AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18474451 — intervention group
Group type: EXPERIMENTAL
Intervention: Effleurage massage therapy (20 min of effleurage on ten occasions)
Number of subjects: 22
Study 18474451 — intervention group
Group type: COMPARATOR
Intervention: Control visits (ten 20-minute visits)
Number of subjects: 22
Study 15598944 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) every 3 weeks (Dq3w)
Number of subjects: 125
Study 15598944 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 40 mg/m(2) given weekly for 6 weeks followed by 2 weeks of rest (Dqw)
Number of subjects: 125
Study 11781120 — intervention group
Group type: EXPERIMENTAL
Intervention: OQLQ (Osteoporosis Quality of Life Questionnaire)
Number of subjects: 338
Study 11781120 — intervention group
Group type: EXPERIMENTAL
Intervention: QUALEFFO (Quality of Life Questionnaire for Patients with Osteoporosis)
Number of subjects: 338
Study 11781120 — intervention group
Group type: COMPARATOR
Intervention: SF-36 (common anchor test)
Number of subjects: 338
Study 9843762 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg/h)
Number of subjects: 0
Study 9843762 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 7866080 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic medicines
Number of subjects: 170
Study 7866080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 2680794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally
Number of subjects: 16
Study 2680794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31760524 — intervention group
Group type: EXPERIMENTAL
Intervention: Second TUR
Number of subjects: 210
Study 30827975 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived importance of ethnic identity
Number of subjects: 0
Study 30827975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to speak tribal language
Number of subjects: 0
Study 28008145 — intervention group
Group type: EXPERIMENTAL
Intervention: High BRCA1 expression (n = 221)
Number of subjects: 528
Study 28008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MSH2 expression (n = 356)
Number of subjects: 528
Study 28008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BRCA1 and high MSH2 (n = 55)
Number of subjects: 528
Study 28008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk group (n = 82)
Number of subjects: 528
Study 28008145 — intervention group
Group type: EXPERIMENTAL
Intervention: High BRCA1 and low MSH2 (n = 67)
Number of subjects: 528
Study 25982539 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab retreatment as needed (300 mg)
Number of subjects: 966
Study 25982539 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab retreatment as needed (150 mg)
Number of subjects: 966
Study 25982539 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab fixed interval (300 mg)
Number of subjects: 966
Study 25982539 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab fixed interval (150 mg)
Number of subjects: 966
Study 23551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg two inhalations twice daily via Turbuhaler®
Number of subjects: 1293
Study 23551359 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 4.5 μg two inhalations twice daily via Turbuhaler®
Number of subjects: 1293
Study 21337428 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 300
Study 21337428 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical therapy
Number of subjects: 300
Study 19708000 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 50
Study 19708000 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg
Number of subjects: 50
Study 19708000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17633357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Colon Dialysis (SCD)
Number of subjects: 293
Study 17633357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 293
Study 17633357 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 293
Study 17633357 — intervention group
Group type: COMPARATOR
Intervention: Control (SCD, HD, PD)
Number of subjects: 293
Study 15041005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep educational program (2-hour interactive course)
Number of subjects: 540
Study 15041005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 540
Study 11249162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tactile stimulation (Group 1)
Number of subjects: 49
Study 11249162 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 49
Study 9515561 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus over 5 minutes followed by continuous i.v. infusion of 50 microg/kg/min over 75 minutes)
Number of subjects: 16
Study 9515561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8070302 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin for 6 months
Number of subjects: 70
Study 8070302 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 70
Study 29929945 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression classifier
Number of subjects: 10785
Study 29929945 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) classifier
Number of subjects: 10785
Study 29929945 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest classifier
Number of subjects: 10785
Study 29929945 — intervention group
Group type: COMPARATOR
Intervention: Baseline ZeroR algorithm
Number of subjects: 10785
Study 26795426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy for depression (n=141)
Number of subjects: 252
Study 26795426 — intervention group
Group type: COMPARATOR
Intervention: Brief psychoeducational intervention (n=111)
Number of subjects: 252
Study 24326967 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin C 0.2 mg/mL
Number of subjects: 87
Study 24326967 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C 0.2 mg/mL
Number of subjects: 87
Study 22117083 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP) measurement
Number of subjects: 461
Study 22117083 — intervention group
Group type: COMPARATOR
Intervention: Manual Office Blood Pressure (MOBP) measurement
Number of subjects: 461
Study 22117083 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AOBP and MOBP to Awake Ambulatory Blood Pressure (AABP)
Number of subjects: 461
Study 20420104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 eggs per week
Number of subjects: 417
Study 20420104 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 eggs per week
Number of subjects: 417
Study 18308687 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF) hospitalization
Number of subjects: 11040
Study 18308687 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of HF
Number of subjects: 11040
Study 18308687 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of death due to HF
Number of subjects: 11040
Study 16444435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day, for 12 weeks)
Number of subjects: 24
Study 16444435 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 24
Study 12859311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 1.5 mg/ml, 10 ml/h (n = 26)
Number of subjects: 90
Study 12859311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg/ml, 3 ml/h (n = 33)
Number of subjects: 90
Study 12859311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 mg/ml, 2 ml/h (n = 31)
Number of subjects: 90
Study 10624999 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 60
Study 10624999 — intervention group
Group type: COMPARATOR
Intervention: desflurane
Number of subjects: 60
Study 10624999 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane
Number of subjects: 60
Study 9179120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 92
Study 9179120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloromyotomy
Number of subjects: 92
Study 8252957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8252957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14
Study 8252957 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 14
Study 8252957 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 14
Study 3900393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal high dose (1000 mg daily)
Number of subjects: 227
Study 3900393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal low dose (750 mg daily)
Number of subjects: 227
Study 3900393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 3900393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (both doses)
Number of subjects: 227
Study 3900393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal high dose vs low dose
Number of subjects: 227
Study 30615231 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1g
Number of subjects: 10
Study 30615231 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 29573224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 3 years
Number of subjects: 1002
Study 29573224 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet for 3 years
Number of subjects: 1002
Study 27480654 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 10 ml (Group A)
Number of subjects: 60
Study 27480654 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine 20 ml (Group B)
Number of subjects: 60
Study 25766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5-10 mg/day)
Number of subjects: 15
Study 22093109 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics treatment
Number of subjects: 102
Study 22093109 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 102
Study 22093109 — intervention group
Group type: EXPERIMENTAL
Intervention: High fecal HBD2 levels at 6 months
Number of subjects: 102
Study 22093109 — intervention group
Group type: EXPERIMENTAL
Intervention: High fecal HNP1-3 levels at 6 months
Number of subjects: 102
Study 22093109 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low or high HBD2 levels at 6 months
Number of subjects: 102
Study 20407630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 0
Study 20407630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0
Study 20407630 — intervention group
Group type: COMPARATOR
Intervention: Post hoc analyses
Number of subjects: 0
Study 17879544 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhongfu Hypotension Capsule (ZHC) - 3 capsules (0.5 g/capsule) twice a day for 4 weeks
Number of subjects: 0
Study 17879544 — intervention group
Group type: COMPARATOR
Intervention: Lotensin Tablet - 1 tablet (10 mg/tab.) once a day for 4 weeks
Number of subjects: 0
Study 15730353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications (specific medications not detailed)
Number of subjects: 357
Study 15730353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 15730353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medications and Placebo
Number of subjects: 357
Study 12142119 — intervention group
Group type: EXPERIMENTAL
Intervention: HERG K897T polymorphism (genotypes AC or CC)
Number of subjects: 187
Study 12142119 — intervention group
Group type: COMPARATOR
Intervention: Genotype AA
Number of subjects: 187
Study 12142119 — intervention group
Group type: EXPERIMENTAL
Intervention: HERG K897T polymorphism (in females)
Number of subjects: 187
Study 10442116 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 65
Study 10442116 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 65
Study 7540606 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Mitomycin C and Bleomycin (group B)
Number of subjects: 49
Study 7540606 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 49
Study 7540606 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Mitomycin C and Bleomycin (group B) in oropharyngeal carcinoma
Number of subjects: 49
Study 7540606 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A) in oropharyngeal carcinoma
Number of subjects: 49
Study 2334326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 50
Study 2334326 — intervention group
Group type: COMPARATOR
Intervention: Pneumotonometer
Number of subjects: 50
Study 2334326 — intervention group
Group type: COMPARATOR
Intervention: Manometer
Number of subjects: 50
Study 375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and penicillin (60 mg/m2/8 h)
Number of subjects: 0
Study 375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (in patients with renal failure)
Number of subjects: 0
Study 375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (constant vs intermittent infusion)
Number of subjects: 0
Study 31640314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gflex+plyo
Number of subjects: 34
Study 31640314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gflex
Number of subjects: 34
Study 31640314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gplyo
Number of subjects: 34
Study 31640314 — intervention group
Group type: COMPARATOR
Intervention: Gcon
Number of subjects: 34
Study 30447045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteric stent removal by string
Number of subjects: 149
Study 30447045 — intervention group
Group type: COMPARATOR
Intervention: Ureteric stent removal by cystoscope
Number of subjects: 149
Study 27884804 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty hours
Number of subjects: 0
Study 27884804 — intervention group
Group type: COMPARATOR
Intervention: Female PGY2 to 3 residents
Number of subjects: 0
Study 27884804 — intervention group
Group type: COMPARATOR
Intervention: Female PGY4 to 5 residents
Number of subjects: 0
Study 25485782 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2/3 h), carboplatin (AUC 5), and bevacizumab (15 mg/kg) administered every 21 days for 6-8 cycles, followed by maintenance therapy with bevacizumab (15 mg/kg) every 21 days for 16 cycles.
Number of subjects: 15
Study 25485782 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and bevacizumab combination therapy.
Number of subjects: 15
Study 23159169 — intervention group
Group type: EXPERIMENTAL
Intervention: High insertion torque (up to 80 N cm)
Number of subjects: 102
Study 23159169 — intervention group
Group type: COMPARATOR
Intervention: Control group (insertion torque between 30 and 45 N cm)
Number of subjects: 102
Study 21292441 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders (ERs)
Number of subjects: 125
Study 21292441 — intervention group
Group type: COMPARATOR
Intervention: No reminder (controls)
Number of subjects: 125
Study 19541014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test before major abdominal surgery
Number of subjects: 77
Study 19541014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test during operation, on first postoperative day, and before discharge
Number of subjects: 77
Study 19541014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH test
Number of subjects: 77
Study 17318618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (5%)
Number of subjects: 204
Study 17318618 — intervention group
Group type: COMPARATOR
Intervention: Arnica (50 g tincture/100 g, DER 1:20)
Number of subjects: 204
Study 15614340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 15614340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11252073 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR; 20 g.d‐1, 5 d)
Number of subjects: 11
Study 11252073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P, maltodextrine)
Number of subjects: 11
Study 11252073 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 11
Study 11252073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study 9333879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements in the forearm of patients with Colles fracture
Number of subjects: 50
Study 9333879 — intervention group
Group type: COMPARATOR
Intervention: Control group without fracture
Number of subjects: 50
Study 8317641 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox with 0.2% isoflurane
Number of subjects: 18
Study 8317641 — intervention group
Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 18
Study 3551506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide
Number of subjects: 23
Study 3551506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30606425 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 30606425 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 28746113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot packs applied for 10 minutes to the lumbar region
Number of subjects: 34
Study 28746113 — intervention group
Group type: COMPARATOR
Intervention: Normal packs applied for 10 minutes to the lumbar region
Number of subjects: 34
Study 25387876 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (escalating voltage: 11.4‐12.0‐13 kV per 1,000 shock waves, 2 Hz)
Number of subjects: 120
Study 25387876 — intervention group
Group type: COMPARATOR
Intervention: Group C (constant voltage: 13 kV, 3,000 shock waves, 2 Hz)
Number of subjects: 120
Study 25387876 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (escalating voltage)
Number of subjects: 120
Study 25387876 — intervention group
Group type: COMPARATOR
Intervention: Group C (constant voltage)
Number of subjects: 120
Study 23311647 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-embedded reproductive health interventions (CERCA)
Number of subjects: 0
Study 23311647 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled study in Managua
Number of subjects: 0
Study 23311647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised controlled study in Cochabamba and Cuenca
Number of subjects: 0
Study 21681167 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 15
Study 21681167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19538334 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium hand-instruments
Number of subjects: 37
Study 19538334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 37
Study 16709303 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 microg, one inhalation, once or twice daily maintenance plus additional doses as needed (1 x SMART or 2 x SMART)
Number of subjects: 465
Study 16709303 — intervention group
Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 microg two inhalations twice daily plus formoterol 4.5 microg as needed (2 x 2 FIX + F)
Number of subjects: 465
Study 16709303 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x SMART
Number of subjects: 465
Study 16709303 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x SMART
Number of subjects: 465
Study 16709303 — intervention group
Group type: COMPARATOR
Intervention: 2 x 2 FIX + F
Number of subjects: 465
Study 15290892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5 mm sutured corneal incision
Number of subjects: 20
Study 15290892 — intervention group
Group type: COMPARATOR
Intervention: 4.0 mm sutureless corneal incision
Number of subjects: 20
Study 11705850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, IFN α‐2b, doxorubicin, and 5‐fluorouracil (PIAF)
Number of subjects: 41
Study 9356636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic (US) findings
Number of subjects: 64
Study 9356636 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic (CT) findings
Number of subjects: 64
Study 7877117 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine monotherapy
Number of subjects: 42
Study 7877117 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine with adjunct sleep deprivation (SD)
Number of subjects: 42
Study 7877117 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine with adjunct bright light (BL)
Number of subjects: 42
Study 7877117 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 42
Study 7877117 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 42
Study 3182456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg x 2 daily)
Number of subjects: 84
Study 3182456 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin (700 mg x 3 daily)
Number of subjects: 84
Study 29583066 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble chicken egg yolk peptides
Number of subjects: 0
Study 27869354 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% twice a day
Number of subjects: 80
Study 27869354 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine difumarate 0.05% twice a day
Number of subjects: 80
Study 27869354 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% four times a day
Number of subjects: 80
Study 27869354 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control group) 0.5% three times a day
Number of subjects: 80
Study 26394887 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 65
Study 26394887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65